Arrowhead Pharmaceuticals Inc.
ARWR
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.36B
Close$
$-3.88
105.9% downside
Current Fair Value
105.9% downsideOvervalued by 105.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.36 Billion |
|---|---|
| Enterprise Value | $10.27 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 1.28 |
| Outstanding Shares | 143,378,000 |
Return
| Return on Equity | -68.73% |
|---|---|
| Return on Assets | -15.15% |
| Return on Invested Capital | -10.77% |
Valuation & Multiples
| P/E Ratio | -29.68 |
|---|---|
| PEG | -273.17 |
| Price to Sales | 16.52 |
| Price to Book Ratio | 22.02 |
| Enterprise Value to Revenue | 15.34 |
| Enterprise Value to EBIT | -52.13 |
| Enterprise Value to Net Income | -33 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 2.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.19
Average shareholder expectationRevenue Estimate
$47.89 M
Average shareholder expectationNext Earnings Call
Expected Date
November 24, 2026
EPS Estimate
$-1.59
Average shareholder expectationRevenue Estimate
$59.19 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4359▼ 9.71% |
|---|---|
| Total Calls | 1,753,000▲ 9.52% |
| Total Puts | 764,100▼ 10.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.88%▼ 0.97% |
|---|---|
| Total Invested | $9.81B▲ 29.46% |
| Investors Holding | 523▲ 62.00% |
ESG Score
No data
About Arrowhead Pharmaceuticals Inc.
CEO: Christopher Anzalone